Journal ArticleDOI
Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study
TLDR
Clinical use of bisphosphonates as an adjuvant therapy for giant cell tumor of bone demonstrated a lower local recurrence rate and the clinical response seems to be more promising in stage III diseases.About:
This article is published in Bone.The article was published on 2008-01-01. It has received 192 citations till now. The article focuses on the topics: Giant-cell tumor of bone & Bisphosphonate.read more
Citations
More filters
Journal ArticleDOI
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
David Thomas,Robert M. Henshaw,Keith M. Skubitz,Sant P. Chawla,Arthur P. Staddon,Jean-Yves Blay,Martine Roudier,Judy Smith,Zhishen Ye,Winnie Sohn,Roger Dansey,Susie Jun +11 more
TL;DR: In this article, the potential therapeutic effect of denosumab, a fully human monoclonal antibody against RANKL, on tumour-cell survival and growth in patients with GCT was investigated.
Journal ArticleDOI
Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
D Branstetter,Scott D. Nelson,J. Carlos Manivel,Jean-Yves Blay,Sant P. Chawla,David Thomas,Susie Jun,Ira Jacobs +7 more
TL;DR: Denosumab treatment of patients with GCTB significantly reduced or eliminated RANK-positive tumor giant cells and reduced the relative content of proliferative, densely cellular tumor stromal cells, replacing them with nonproliferative, differentiated, densely woven new bone.
Journal ArticleDOI
Osteoclasts: more than ‘bone eaters’
TL;DR: This work considers how osteoclast signals may contribute to bone formation by osteoblasts and to the pathology of bone lesions such as fibrous dysplasia and giant cell tumors and reviews the interaction of osteoclasts with the hematopoietic system, including the stem cell niche and adaptive immune cells.
Journal ArticleDOI
Giant Cell Tumor of Bone: Risk Factors for Recurrence
TL;DR: Intralesional surgery with polymethylmethacrylate is recommended for the majority of primary GCTs and the potential for metastases should not by itself create an indication for wide resection of primary tumors.
Journal ArticleDOI
Osteonecrosis of the jaw in a patient on Denosumab.
TL;DR: Osteonecrosis of the jaws incidence correlation with BP potency suggests that inhibition of osteoclast function and differentiation might be a key factor in the pathophysiology of the disease.
References
More filters
Journal ArticleDOI
Giant-cell tumor of bone.
TL;DR: Of the fifty-one local recurrences that were seen after treatment at the Istituto Rizzoli, 90 per cent appeared in the first three years after surgery, and these results did not correlate with the radiographic grade of the lesion.
Journal Article
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Lee S. Rosen,David Gordon,Mary Kaminski,Anthony Howell,Andrew R. Belch,John R. Mackey,J. Apffelstaedt,Mohamed Hussein,Robert E. Coleman,Dirk J. Reitsma,John J. Seaman,Bee Lian Chen,Yvonne Ambros +12 more
TL;DR: Zoledronic acid (4 mg) via 15-minute intravenous infusion was as effective and well tolerated as 90 mg of pamidronate in the treatment of osteolytic and mixed bone metastases/lesions in patients with advanced breast cancer or multiple myeloma.
Journal ArticleDOI
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Allan Lipton,Richard L. Theriault,Gabriel N. Hortobagyi,Joseph F. Simeone,Robert Knight,Kathleen Mellars,Dirk J. Reitsma,Maika Heffernan,John J. Seaman +8 more
TL;DR: Pamidronate therapy has been shown to reduce skeletal complications effectively for up to 12 months in breast carcinoma patients with bone metastases as discussed by the authors, and the results of two randomized, multicenter, randomized, double-blind, placebo-controlled intervention trials conducted at academic and community oncology centers were combined to provide a large data set with which to evaluate the long term efficacy and safety of pamidroneate therapy.
Journal ArticleDOI
Recurrence of giant-cell tumors of the long bones after curettage and packing with cement.
Richard J. O'Donnell,Dempsey S. Springfield,Haresh Motwani,John E. Ready,Mark C. Gebhardt,Henry J. Mankin +5 more
TL;DR: The nine-year experience with sixty patients who had had a giant-cell tumor of a long bone was reviewed to determine the rate of recurrence after treatment with curettage and packing with polymethylmethacrylate cement.
Journal ArticleDOI
Giant-cell tumor of bone: analysis of two hundred and eight cases in chinese patients
TL;DR: This work proposes excision and curettage with bone-grafting as the most suitable method of treatment in the majority of patients with giant-cell tumor of bone.